Samsung Biologics
Trending Articles
Related Content
Manufacturing
Overcoming bio/pharmaceutical production hurdles: an industry insider perspective
From F-gas regulation to finance and from biologics to personalised medicines, the global drug production environment faces a number of challenges that could potentially stifle innovation and profitability. Dr Kevin Robinson (KSR) recently spoke to key players in the supplier and outsourcing community to better understand what services and solutions are available to keep the pipeline flowing
Manufacturing
Unearthing the potential of CDMO services to accelerate complex biologics development
The biologics landscape continues to transform in response to technological advancements and a growing understanding of molecular biology and biochemistry. As a result, an influx of both novel and complex therapeutics is entering the development pipeline, including bispecific antibodies (BsAbs), fusion proteins and antibody-drug conjugates (ADCs). However, these new moieties bring unique and potentially unfamiliar development and manufacturing difficulties
Manufacturing
Bioprocessing in the balance: part I
Dr Kevin Robinson recently caught up with Na Hye-jung, Head of Global Regulatory Affairs at Samsung Biologics, to pose the question: how do you solve the process optimisation equation of speed-to-market and cost efficiencies while maintaining a safe environment for both operators and end users?